Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight
  • Published:

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

Leukemia volume 17, pages 1448–1453 (2003)Cite this article

Abstract

We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (<35% Ph-negative marrow metaphases) at 3 months as principal independent predictive factors and incorporated them into a three-tier prognostic scoring system for individual patients. For patients in the low-, intermediate- and high-risk groups, the probabilities of survival at 24 months were 100, 82 and 40% (P<0.0001) and progression-free survival 100, 66 and 15% (P<0.0001), respectively. This Hammersmith prognostic scoring system was validated with an independent cohort of patients treated at another UK centre.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356.

    CAS  PubMed  Google Scholar 

  2. Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002; 99: 2304–2309.

    Article  CAS  Google Scholar 

  3. Goldman JM, Druker BJ . Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039–2042.

    Article  CAS  Google Scholar 

  4. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074–3081.

    Article  CAS  Google Scholar 

  5. Druker BJ, Lydon NB . Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3–7.

    Article  CAS  Google Scholar 

  6. Deininger MWN, Goldman JM, Lydon NB, Melo JV . The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90: 3691–3698.

    CAS  Google Scholar 

  7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  Google Scholar 

  8. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042.

    Article  CAS  Google Scholar 

  9. O'Brien SG, Guilhot F, Larson RA, on behalf of the IRIS Investigators. Interferon and low dose cytarabine compared with imatinib for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  CAS  Google Scholar 

  10. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  Google Scholar 

  11. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441–1446.

    Article  CAS  Google Scholar 

  12. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789–799.

    CAS  PubMed  Google Scholar 

  13. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858.

    Article  CAS  Google Scholar 

  14. Frassoni F, Podesta M, Piaggio G, Rosti V, Pitto A, Benvenuto F et al. Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time. Br J Haematol 1999; 104: 538–545.

    Article  CAS  Google Scholar 

  15. Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Lorraine Armstrong who was responsible coordinating the care of patients in these studies. We thank also the many medical and nursing colleagues who have participated in the treatment of patients. We thank Andrew Chase for cytogenetic analyses. We thank staff of Novartis Pharma (Basel) for valuable help and supply of Glivec. This study was supported in part by the Leukaemia Research Fund.

Author information

Authors and Affiliations

  1. Department of Haematology, Imperial College London at Hammersmith Hospital, London, UK

    D Marin, S Marktel, M Bua, R M Szydlo, A Franceschino, I Nathan, N Foot, C Crawley, T Na Nakorn, E Olavarria, J M Goldman & J F Apperley

  2. Department of Haematology, Royal Victoria Infirmary, Newcastle, UK

    A Lennard, A Neylon & S G O'Brien

Authors
  1. D Marin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Marktel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Bua
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R M Szydlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Franceschino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Nathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Foot
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Crawley
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Na Nakorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Olavarria
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Lennard
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Neylon
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S G O'Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J M Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J F Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marin, D., Marktel, S., Bua, M. et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 17, 1448–1453 (2003). https://doi.org/10.1038/sj.leu.2402996

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402996

Keywords

This article is cited by

Search

Advanced search

Quick links